U.S. Heart Failure Drugs Market Size, Share & Forecast 2026–2032

ID: MR-11041 | Published: November 2026
Download PDF Sample

Report Highlights

  • ✓Country: U.S.
  • ✓Market: Heart Failure Drugs Market
  • ✓Market Size 2024: USD 13.8 billion
  • ✓Market Size 2032: USD 19.6 billion
  • ✓CAGR: 4.5%
  • ✓Base Year: 2025
  • ✓Forecast Period: 2026–2032
Market Growth Chart
Want Detailed Insights - Download Sample
Analyst Findings and Recommendations
FINDING 01
Entresto Generic Erosion Accelerating: Novartis faces generic sacubitril/valsartan entry while Medicare negotiated prices for Entresto take effect January 2026, compressing the ARNI franchise faster than payer models assumed. SGLT2 inhibitors from AstraZeneca and Boehringer Ingelheim capture the displaced prescribing volume through guideline-directed therapy.
FINDING 02
Monitoring Expands Drug Demand: Consensus expects remote monitoring such as Abbott's CardioMEMS to shrink drug demand. Instead, hemodynamic monitoring identifies more patients for Bayer's Kerendia and SGLT2 inhibitors, expanding the treatable population in the U.S.
ANALYST RECOMMENDATION

Analyst Recommendation — Secure Formulary Positions Now: Generic makers and branded challengers should secure Medicare Part D formulary positions before the January 2026 negotiated price reset. Placement decided now determines share for the decade, because negotiated reimbursement resets economics for every ARNI and SGLT2 product.

Heart Failure Drugs in the U.S.: Competitive Overview

The U.S. heart failure drugs market is moderately concentrated, with a small group of branded innovators controlling most prescription value. Novartis, AstraZeneca, Boehringer Ingelheim and Bayer hold the franchises that define guideline-directed medical therapy, while generic manufacturers such as Teva and Sandoz compete on older molecules including beta-blockers and diuretics. International originators dominate branded revenue, while U.S.-headquartered Viatris and the wholesalers McKesson, Cardinal Health and Cencora control generic supply and distribution.

Competitive advantage in this market turns on payer access rather than molecule science alone. Outcomes trial data, Medicare Part D formulary placement and 340B contract pricing determine which product captures primary care prescribing. Companies that combine HFpEF and HFrEF labels with cardiology sales coverage, such as Bayer with Kerendia and AstraZeneca with Farxiga, convert clinical evidence into share, while late-entry rivals face rebate pressure from pharmacy benefit managers including CVS Caremark, Express Scripts and OptumRx.

Demand Drivers Shaping Heart Failure Drugs in the U.S.

Aging demographics drive the strongest volume growth. Roughly six million Americans live with heart failure, and prevalence rises sharply after age 65, expanding the Medicare Part D population that anchors branded sales. Novartis and AstraZeneca benefit most, because Entresto and Farxiga carry Medicare reimbursement and established guideline status across both reduced and preserved ejection fraction patients, giving them durable prescribing momentum before generic competition scales meaningfully.

Diagnostic and therapeutic advances widen the treatable pool. Guideline updates from the American College of Cardiology and American Heart Association and FDA label expansions for finerenone and SGLT2 inhibitors move patients with preserved ejection fraction into drug eligibility. Bayer's Kerendia and Boehringer Ingelheim's Jardiance gain most from this shift, while device makers such as Abbott, selling CardioMEMS monitoring, benefit indirectly by identifying patients who then start therapy.

Competitive Restraints and Market Challenges

Price competition is intensifying as the Inflation Reduction Act's Medicare negotiation takes effect in 2026. The negotiated maximum fair price for Entresto, Farxiga and Jardiance, all selected in the first cohort, reduces net revenue for incumbents and pressures challengers to price aggressively for formulary access. Generic sacubitril/valsartan from multiple filers compresses the ARNI segment directly across pharmacy benefit channels, leaving Novartis to defend share through pricing and contracting.

Talent and infrastructure gaps constrain challengers. Field cardiology sales forces are expensive to build, and small biotechs lack the real-world evidence infrastructure payers now require. Regulatory compliance costs under the 340B program and Medicare reporting rules add administrative burden, while the shortage of clinical pharmacists and specialist heart failure nurses limits adoption of complex multi-drug regimens in community practice. Smaller firms therefore cede ground to Boehringer Ingelheim and AstraZeneca, whose established cardiology reach absorbs these costs.

Growth Opportunities for Market Players

Heart failure with preserved ejection fraction remains the largest unmet need in the U.S. Bayer's Kerendia and SGLT2 inhibitors now carry labels spanning ejection fraction ranges, so players that generate Medicare-compatible outcomes evidence can displace older diuretic-based regimens. Cytokinetics and other cardiac myosin developers target obstructive phenotypes, adding a specialist niche beyond the established classes. Companies that secure early pilot contracts with integrated delivery networks such as Kaiser Permanente and HCA Healthcare can lock adoption before generic entry.

Post-discharge care represents a second opening. Heart failure readmissions remain a Medicare penalty priority, so manufacturers and digital health firms that bundle therapy initiation with follow-up monitoring, such as Abbott's CardioMEMS sensor programs, can win hospital formulary placement. Wholesalers McKesson and Cencora also gain by offering specialty pharmacy services that reduce discontinuation rates among patients starting multi-drug regimens, a service that generics cannot replicate at scale.

Market at a Glance

MetricValue
Market Size 2024USD 13.8 billion
Market Size 2032USD 19.6 billion
Growth Rate (CAGR)4.5%
Most Critical Decision FactorMedicare Part D formulary placement and negotiated pricing
Largest RegionSouth Census Region
Competitive StructureModerately concentrated, led by branded originators

Leading Market Participants

  • Novartis
  • AstraZeneca
  • Boehringer Ingelheim
  • Bayer
  • Merck & Co.
  • Abbott
  • Teva Pharmaceutical
  • Sandoz
  • CSL Vifor
  • Viatris

Regulatory and Policy Environment

The Inflation Reduction Act directly reshapes competition. Medicare's drug price negotiation program, administered by CMS, set negotiated prices for Entresto, Farxiga and Jardiance effective in 2026, while the Part D redesign caps beneficiary out-of-pocket spending and shifts liability to manufacturers and plans. FDA oversight under the Hatch-Waxman Act governs generic entry, and Paragraph IV certifications determine when challengers can launch. Patent litigation outcomes therefore set competitive timelines more than clinical data does.

The 340B Drug Pricing Program, administered by HRSA, lowers acquisition costs for safety-net hospitals and shapes channel economics for branded cardiology drugs. State prescription drug affordability boards in Colorado and Maryland expand scrutiny of high-cost products, while CMS Part D formulary rules determine which heart failure agents plans must cover. Compliance with these overlapping rules adds cost that favors large incumbents with dedicated market access teams over smaller challengers.

Competitive Outlook for U.S. Heart Failure Drugs

By 2032, the market will consolidate around fewer branded franchises as generic sacubitril/valsartan and later entrants erode prices. Novartis will manage Entresto as a declining cash franchise, while AstraZeneca and Boehringer Ingelheim defend Farxiga and Jardiance through indication breadth across chronic kidney disease, diabetes and heart failure. Branded leaders will retain most revenue despite volume growth in generic heart failure medicines, because payers reward incumbents with clinical evidence libraries.

Device companies and digital health platforms will reshape prescriber decisions at the margin. Abbott's CardioMEMS and Medtronic's monitoring offerings will increasingly identify patients earlier, feeding drug initiation rates for finerenone and SGLT2 inhibitors. Companies that combine evidence generation, Medicare contracting and hospital integration will hold competitive advantage, while single-product challengers face consolidation or exit. Expect bolt-on acquisitions of mid-stage cardiac assets by Bayer, Merck and CSL Vifor as portfolio gaps emerge.

Frequently Asked Questions

Novartis, AstraZeneca and Boehringer Ingelheim hold the largest branded positions through Entresto, Farxiga and Jardiance. Their franchises span sacubitril/valsartan and SGLT2 inhibitors, which anchor guideline-directed therapy.
Generic makers compete primarily on price and formulary inclusion once patent exclusivity ends, as seen with sacubitril/valsartan entry. Success depends on securing pharmacy benefit manager contracts and maintaining reliable supply.
Negotiated maximum fair prices for Entresto, Farxiga and Jardiance take effect in 2026 and reset net revenue for incumbents. Challengers gain relative pricing room while originators shift toward indication expansion.
CVS Caremark, Express Scripts and OptumRx control formulary placement and rebate negotiation for most commercially insured patients. Brands without rebate-funded access rarely reach meaningful prescriber-level share.
Device makers such as Abbott do not displace drugs; they identify eligible patients and expand prescribing. Their monitoring data increases demand for therapies such as Kerendia and SGLT2 inhibitors.

Market Segmentation

By Drug Class
  • Angiotensin Receptor Neprilysin Inhibitors
  • SGLT2 Inhibitors
  • Mineralocorticoid Receptor Antagonists
  • Beta-Blockers
  • Loop Diuretics
By Distribution Channel
  • Retail Pharmacies
  • Hospital Pharmacies
  • Mail-Order Pharmacies
  • Specialty Pharmacies
By End User
  • Hospitals
  • Cardiology Clinics
  • Primary Care Practices
  • Long-Term Care Facilities

Table of Contents

Chapter 01 Methodology and Scope
1.1 Research Methodology
1.2 Scope and Definitions
1.3 Data Sources
Chapter 02 Executive Summary
2.1 Report Highlights
2.2 Market Size and Forecast 2024-2032
Chapter 03 U.S. Heart Failure Drugs - Market Analysis
3.1 Market Overview
3.2 Growth Drivers
3.3 Restraints
3.4 Opportunities
Chapter 04 Drug Class Insights
4.1 Angiotensin Receptor Neprilysin Inhibitors
4.2 SGLT2 Inhibitors
4.3 Mineralocorticoid Receptor Antagonists
4.4 Beta-Blockers
4.5 Others
Chapter 05 Distribution Channel Insights
5.1 Retail Pharmacies
5.2 Hospital Pharmacies
5.3 Mail-Order Pharmacies
5.4 Specialty Pharmacies
5.5 Others
Chapter 06 End User Insights
6.1 Hospitals
6.2 Cardiology Clinics
6.3 Primary Care Practices
6.4 Long-Term Care Facilities
6.5 Others
Chapter 07 Competitive Landscape
7.1 Market Players
7.2 Leading Market Participants
7.2.1 Novartis
7.2.2 AstraZeneca
7.2.3 Boehringer Ingelheim
7.2.4 Bayer
7.2.5 Merck & Co.
7.2.6 Abbott
7.2.7 Teva Pharmaceutical
7.2.8 Sandoz
7.2.9 CSL Vifor
7.2.10 Viatris
7.3 Regulatory Environment
7.4 Outlook

Research Framework and Methodological Approach

Information
Procurement

Information
Analysis

Market Formulation
& Validation

Overview of Our Research Process

MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.

1. Data Acquisition Strategy

Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.

Secondary Research
  • Company annual reports & SEC filings
  • Industry association publications
  • Technical journals & white papers
  • Government databases (World Bank, OECD)
  • Paid commercial databases
Primary Research
  • KOL Interviews (CEOs, Marketing Heads)
  • Surveys with industry participants
  • Distributor & supplier discussions
  • End-user feedback loops
  • Questionnaires for gap analysis

Analytical Modeling and Insight Development

After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.

2. Market Estimation Techniques

MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.

Bottom-up Approach

Country Level Market Size
Regional Market Size
Global Market Size

Aggregating granular demand data from country level to derive global figures.

Top-down Approach

Parent Market Size
Target Market Share
Segmented Market Size

Breaking down the parent industry market to identify the target serviceable market.

Supply Chain Anchored Forecasting

MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.

Supply-Side Evaluation

Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.

3. Market Engineering & Validation

Market engineering involves the triangulation of data from multiple sources to minimize errors.

01 Data Mining

Extensive gathering of raw data.

02 Analysis

Statistical regression & trend analysis.

03 Validation

Cross-verification with experts.

04 Final Output

Publication of market study.

Client-Centric Research Delivery

MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.